TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01982955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was administered at a dose of 75 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered intravenously on Day 1 of each 21-day cycle at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
Study: NCT03616912

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT01995695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine
Description: Participants will receive approximately 10\^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine
Description: Participants will receive approximately 10\^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated subvirion H7N9 influenza vaccine
Description: Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated subvirion H7N9 influenza vaccine
Description: Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.
Study: NCT03383328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID + prednisolone, preoperative
Description: Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID + prednisolone, postoperative
Description: Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID, preoperative
Description: Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID, postoperative
Description: Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drop-less surgery
Description: A depot of 0.5 ml Dexamethason Krka 4 mg/ml solution for injection/infusion is administered during cataract surgery.
Study: NCT02782416

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Examination of latent tuberculosis

Intervention type: OTHER
Group type: OTHER
Intervention: Examination of latent tuberculosis
Study: NCT05843526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental healing abutment
Description: Implant placement (Straumann) Experimental abutment made of titanium, PEEK polyetheretherketone, resin was randomly assessed to the implant site.~Abutment screw channel was filled with Teflon and closed with resin composite. Mouthwash based 0.2% chlorhexidine for 10 days and analgesics (ibuprofen 400 mg, up to 4/d) if necessary.~After 8 weeks, harvesting of the soft tissues around experimental abutment with experimental abutment using a custom-made guide was placed on the experimental abutment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental healing abutment
Description: Implant placement (Straumann) Experimental abutment made of titanium, PEEK polyetheretherketone, resin was randomly assessed to the implant site.~Abutment screw channel was filled with Teflon and closed with resin composite. Mouthwash based 0.2% chlorhexidine for 10 days and analgesics (ibuprofen 400 mg, up to 4/d) if necessary.~After 8 weeks, harvesting of the soft tissues around experimental abutment with experimental abutment using a custom-made guide was placed on the experimental abutment
Study: NCT02782416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Examination of latent tuberculosis
Study: NCT04115943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment protocol for neck pain
Description: The protocol to be used in the study is in accordance with the latest guidelines for the treatment of neck pain associated with limited mobility for patients in the chronic phase. The followed techniques will be performed: i) manual therapy - manipulation or mobilization of the upper cervical spine, manipulation or mobilization of the cervical, cervicothoracic and thoracic regions, manual cervical traction, release of the cervical muscles and muscles of the scapulothoracic region; ii) exercises - strengthening and resistance exercises for the muscles of the scapular girdle, coordination, proprioception and postural training of the cervical and scapulothoracic regions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment protocol for neck pain
Description: The protocol to be used in the study is in accordance with the latest guidelines for the treatment of neck pain associated with limited mobility for patients in the chronic phase. The followed techniques will be performed: i) manual therapy - manipulation or mobilization of the upper cervical spine, manipulation or mobilization of the cervical, cervicothoracic and thoracic regions, manual cervical traction, release of the cervical muscles and muscles of the scapulothoracic region; ii) exercises - strengthening and resistance exercises for the muscles of the scapular girdle, coordination, proprioception and postural training of the cervical and scapulothoracic regions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol for release of tongue muscles
Description: . The aim is the relaxation of the suprahyoid muscles (mylohyoid, geniohyoid, digastric and stylohyoid) as well as the cervical fascia of the anterior region and soft tissues of the region of the pharynx and larynx.
Study: NCT02574065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938
Description: Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: The placebo consists of an identical formulation without L. reuteri DSM 17938
Study: NCT01456806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Education
Description: Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
Study: NCT02022878

Intervention type: PROCEDURE
Intervention: PCI of CTO
Study: NCT00993356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative lanreotide treatment
Description: Patients received lanreotide for 16 weeks before the surgical resection \[starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH \> 5 mU/L on GH day curve (GHDC)\] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transsphenoidal surgery
Study: NCT04122040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roxithromycin 300 MG
Description: Roxithromycin 300 mg oral per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one table oral once dialy
Study: NCT03935152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone
Description: dydrogesterone capsule
Study: NCT01587157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: capnography
Study: NCT01205087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OKT3
Description: Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OKT3
Description: Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OKT3
Description: Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OKT3
Description: Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
Study: NCT01876225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forced coughing during cervical punch biopsy
Study: NCT00271401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angioplasty

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intracoronary Stent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracoronary Stent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abxicimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abxicimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparin
Study: NCT03752658

Intervention type: DRUG
Intervention: Tenofovir Alafenamide
Description: The dose of tenofovir alafenamide (TAF) will be 25mg tablet taken orally once daily with food for 36 months, patients will be treated with TAF alone or in combination with anti-HBV agents
Study: NCT04496011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training with cycle ergometer
Description: Patients start with an initial warm-up of 2 minutes, with rotations per minute free, without load. Progressively, the load of the exercise cycle increases every minute up to the supported limit or up to 60% - 70% of maximum heart rate (HRmax). The training will be carried out for 20 continuous minutes, being interrupted whenever the heart rate (HR) reaches 90% of the maximum expected for the age and / or the loss of effort perceived in the BORG scale, above 8 on a scale of 0 to 10.
Study: NCT03659877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants will undertake a variety of typical daily physical activities, such as laying down, sitting, walking whilst wearing accelerometers and gas analysis equipment.
Study: NCT00808548

Intervention type: OTHER
Intervention: counseling, emotional support

Intervention type: OTHER
Intervention: emotional support
Description: emotional support during the interview

Intervention type: OTHER
Intervention: emotional support
Description: emotional supporting during the interview
Study: NCT02899702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIVIGEN (CSL Behring)
Description: Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs).~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin
Description: 4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study.
Study: NCT03902834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Use the wearable technology (Fitbit) and proven behavioural change techniques to precondition patients prior to lung cancer surgery
Study: NCT00391625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA-GCB
Description: 15-60 U/kg every other week via intravenous infusion
Study: NCT00410605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study: NCT03935152

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule
Study: NCT04503629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium
Description: Anaprazole Sodium 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium
Description: Anaprazole Sodium 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole sodium
Description: Rabeprazole sodium 10mg
Study: NCT03110783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioseal
Description: Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.
Study: NCT05711589

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBA was performed under intracardiac echocardiography guidance without fluoroscopy
Description: Zero-X group: Patients undergoing ICE-guided CBA

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cryoablation (CBA) was performed under fluoroscopic guidance
Description: cryoablation (CBA) was performed under fluoroscopic guidance
Study: NCT01812265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: single Dose
Study: NCT01763502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOOD
Description: The food transfers consist of multiple-micronutrient-fortified corn soy blend (CSB), oil, and sugar, totaling approximately 1200 calories per day per child and including 99% of iron requirements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CASH
Description: Cash transfers equal the estimated value of the food basket if purchased in the market.
Study: NCT01812265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: single Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Dose
Study: NCT00787280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Ketogenic Diet (LCKD)
Description: participants will follow a low carbohydrate ketogenic diet for six weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Fat Diet (LFD)
Description: particpants will follow a low fat diet for six weeks
Study: NCT01414686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Commercially-Available Interactive Video Games
Description: Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included Wii Sports and Wii Fit; PS games included the EyeToy Play 2 and Kinetic. Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.~Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours.
Study: NCT03389490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 300 UNT/ML
Description: Self titration of insulin glargine U300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neutral protamine hagedorn insulin
Description: Self titration of NPH insulin
Study: NCT01074086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD 001
Description: RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
Study: NCT00501865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW273225
Description: GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW273225
Description: GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.
Study: NCT00696839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: 3 sessions of CBT: introduction of CBT, training in relaxation and guided imagery, and troubleshooting/closure. 50 minute sessions with an HIV-experienced treating psychologist in Beck-type CBT. Participants will be given an audiorecording of the 2nd session to be used in private home practice, as desired.
Study: NCT00180583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guidant GALILEO Intravascular Radiotherapy System
Description: Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
Study: NCT00500825

Intervention type: PROCEDURE
Intervention: Measurement of Resting Energy Expenditure
Description: Non-invasive measurement of Resting Energy Expenditure
Study: NCT04735991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kapok Initiative
Description: The detailed process is:~1. After randomization, the Kapok assistant will contact the patient's family~2. The family of the patient joins the Kapok Initiative. They will participate in a 60-minute training program for 27 days, which is taught online by experts; The contents of the lectures are as follows: 1) Doctors are also mortal; 2) New medicines and new therapies; 3) Alternative therapies; 4) Don't panic during the operation; 5) Pain relief; 6) Side effects of treatment; 8) About the truth; 9) New topics; 10) Anti-cancer cost-effectiveness; 11) Medical insurance; 12) Commercial medical insurance; 13) Exercise and rehabilitation; 14) Nutrition and Foods to increase leukocytes level; 15) Long-term persistence; 16) Acceptance Change; 17) Two new roles; 18) Future expectation.
Study: NCT03029091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: Losartan potassium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: Losartan potassium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: Losartan potassium
Study: NCT02449590

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Onion powder
Description: Hot meals with onion powder; 10 g/day onion powder corresponding to 100 g/day fresh onion in meals with potato and beef Intervention period 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hot meals without onion powder; Control meal with potato, beef, soy protein, and sucrose to match macronutrient composition of active treatment
Study: NCT00604045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Description: The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Condition (ACC)
Description: The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
Study: NCT03220386

Intervention type: OTHER
Group type: OTHER
Intervention: Decolonization by nasal Octinidin treatment and skin washings
Description: Patients receive nasal Octinidin treatment and skin washings for five consecutive days